Lipid levels correlate with neuronal and dopaminergic markers during the differentiation of SH-SY5Y cells

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 12,6 MB, PDF-dokument

Parkinson's Disease (PD) is characterised by the loss of dopaminergic neurons and the deposition of protein inclusions called Lewy Bodies (LBs). LBs are heterogeneous structures composed of protein and lipid molecules and their main constituent is the presynaptic protein α-synuclein. SH-SY5Y cells are neuroblastoma cells commonly used to model PD because they express dopaminergic markers and α-synuclein and they can be differentiated into neuronal cells using established protocols. Despite increasing evidence pointing towards a role of lipids in PD, limited knowledge is available on the lipidome of undifferentiated and differentiated SH-SY5Y cells. Using a combination of lipidomics, proteomics, morphological and electrophysiological measurements, we identified specific lipids, including sphingolipids, whose levels are affected by the differentiation of SH-SY5Y neuroblastoma cells and found that the levels of these lipids correlate with those of neuronal and dopaminergic markers. These results provide a quantitative characterisation of the changes in lipidome associated with the differentiation of SH-SY5Y cells into more neuronal and dopaminergic-like phenotype and serve as a basis for further characterisation of lipid disruptions in association with PD and its risk factors in this dopaminergic-like neuronal cell model.

OriginalsprogEngelsk
Artikelnummer167212
TidsskriftBiochimica et Biophysica Acta - Molecular Basis of Disease
Vol/bind1870
Udgave nummer6
Antal sider8
ISSN0925-4439
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
This work was supported by the Independent Research Fund Denmark (2067-00053B (EMS)), Sino-Danish Center for Education and Research (118930 (JNE, KAK)), Lundbeck Foundation (R314-2018-3493 (FRM, CG)), Carlsberg Foundation (CF19-0382 (SSM, FRM, CG)), Novo Nordisk Foundation (NNF20OC0059417 (CG), NNF17OC0029432 (KM)) and Parkinsonforeningen (R16-A250-B174, R37-A805-B174, R54-A1270-B174 (FRM, CG)). We thank the Lipidomics Core Facility (DCI) for access to materials, instrumentations, and expertise.

Publisher Copyright:
© 2024 The Authors

ID: 393775634